CTI-Medidata partner to adopt Remote Source Review in clinical trials
Category: #health  By Saipriya Iyer  Date: 2020-07-10
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

CTI-Medidata partner to adopt Remote Source Review in clinical trials

CTI Clinical Trial and Consulting Services will reportedly adopt Remote Source Review of Medidata. Medidata is the end-to-end solutions provider to support the clinical trials. This contract research organization will use the service to upgrade the remote monitoring & document review process for various global studies, including projects related to COVID-19.

The coronavirus pandemic has increased the burden on medical professionals in developing drugs or vaccines due to travel restrictions and limited access to the clinical research sites. Medidata has been supporting various researchers in advancing the clinical trials during the unprecedented times. The company significantly aligns its imaging workflow solution to remotely, securely, and rapidly assist researchers in source document review and critical document acquisition.

According to Medidata’s co-founder and co-CEO, Glen de Vries, the company has strategized upon developing & deploying the technology that is necessary to ensure high discoveries. It is excited to partner with CTI to advance the clinical trials to treat various patients suffering from infectious diseases and cancer. The support services offered by the company will considerably lead to medical progress and help tackle the pandemic during this crucial period.

Remote Source Review of Medidata is a quick-to-implement technology that is built on its Rave Imaging system. The solution has been deployed already in over 15,000 clinical sites. It is valuable for use especially when clinical studies have critical timelines. It also helps the researchers when there are no secured options to de-identify, review, collect, and redact PII (Personally Identifiable Information). Additionally, it improves the CRA (clinical research associate) productivity by lowering travel costs and time.

As per the statement made by Timothy Schroeder, CTI’s founder and CEO, standardizing trials with Medidata technology and improving the remote monitoring capabilities are highly critical during the ongoing coronavirus pandemic. The company is targeting to reduce the disruptions to research, accelerate the virtual trial management, ensure data collection & integrity, and remotely manage source documents.

Source credit:

https://www.businesswire.com/news/home/20200708005231/en/Medidata-Partners-CTI-Remote-Source-Review-Clinical



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

Stc Bahrain, Crayon & Microsoft partner to equip firms with new tech

Stc Bahrain, Crayon & Microsoft partner to equip firms with new tech

By Saipriya Iyer

Stc Bahrain, a leading digital enabler, inked a strategic alliance agreement with Crayon and Microsoft to provide Microsoft services portfolio to its business clients. As part of its collaboration with Crayon, a Micros...

Retailers under pressure to offer value despite declining sales

Retailers under pressure to offer value despite declining sales

By Saipriya Iyer

According to credible sources, retailers are being forced to strengthen their value credentials, as the budgets of consumers become more constrained throughout the holiday season.

Volatus Aerospace acquires iRed Limited to expand presence in UK

Volatus Aerospace acquires iRed Limited to expand presence in UK

By Saipriya Iyer

Volatus Aerospace Corp. recently announced that it had signed an agreement to acquire iRed Limited, a British company that specializes in drone services and training. The acquisition will reportedly create a foundation...